The first patent is for the use of lenzilumab to reduce nongranulocyte-macrophage colony-stimulating factor (GM-CSF) cytokines/chemokines that contribute to immunotherapy-related toxicity. The second patent covers lenzilumab's use in improving the efficacy and durability of immunotherapy.

Lenzilumab binds to and neutralizes GM-CSF -- a key initiator of the inflammatory cascade triggering immunotherapy-related toxicities, including cytokine storm and neurotoxicity. These conditions have prolonged hospitalization and intensive care unit stays.

Neutralizing the activity of GM-CSF signaling reduces downstream pro-inflammatory mediators and nullifies cytokine response syndrome while also improving T-cell function, Humanigen said.

Humanigen, Avid enter COVID-19 therapy manufacturing agreement
Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production...

Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...

Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...

Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...

Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab....